WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Danny A. Mammo, MD, presents data investigating the 0.18 mg fluocinolone acetonide implant for the treatment of noninfectious uveitis in the posterior segment.
According to Mammo, 80% of patients included in the study showed one or more recurrence of uveitis within a year prior to implantation, a number which dropped to 10% at 24 months after implantation.
“This 24-month data for the CALM study shows us that the fluocinolone acetonide implant is effective in treating noninfectious uveitis affecting the (Read more...)